Pan Cancer T

Executive Summary

Pan Cancer T is a Netherlands-based biotechnology company founded in 2019, dedicated to developing next-generation T cell receptor (TCR)-T cell therapies for solid tumors. The company's proprietary platform focuses on engineering patients' own immune cells to achieve enhanced T cell fitness and persistence, aiming to overcome the immunosuppressive tumor microenvironment that often limits the efficacy of existing cell therapies. By targeting challenging solid cancers with novel TCRs, Pan Cancer T seeks to address significant unmet medical needs in oncology. The company operates in the competitive cell and gene therapy landscape, leveraging its unique approach to T cell engineering to differentiate from other TCR-T and CAR-T platforms. While still in early stages with no disclosed pipelines, the company's scientific premise aligns with industry trends toward improving T cell functionality and durability in solid tumors.

Upcoming Catalysts (preview)

• Q1 2027IND submission for lead TCR-T candidate45% success
• Q3 2026Preclinical proof-of-concept data publication70% success
• Q2 2027Partnership or licensing deal with larger biopharma30% success